Summary & Overview
HCPCS G9089: Colon Cancer, Adenocarcinoma Predominant, Disease Status
HCPCS Level II code G9089 identifies disease-status reporting for colon cancer when invasive adenocarcinoma is the predominant cell type and the extent of disease is unknown, staging is pending, or the status is not listed. The code is specific to use within a Medicare-approved demonstration project and functions as a classification for disease status documentation rather than a procedure or treatment code. Nationally, accurate use of this code supports consistent reporting in demonstration settings and can influence data collection on staging completeness and program evaluation.
Key payers referenced in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise understanding of the clinical context and appropriate site-of-service expectations for the code, an overview of payers considered in benchmarking, and the policy context that limits this code to Medicare demonstration projects. The publication outlines where this code fits in oncology service lines, clarifies what information is represented by the code, and highlights data limitations where input fields are not provided.
The report provides: a description of the code and its clinical meaning; payer coverage scope and relevance for national benchmarking; operational considerations for oncology and outpatient settings; and guidance on which elements are unavailable in the input. Data not available in the input is noted explicitly where applicable.
Billing Code Overview
HCPCS Level II code G9089 describes oncology disease status for colon cancer, limited to invasive cancer with adenocarcinoma as the predominant cell type, where the extent of disease is unknown, staging is in progress, or the status is not listed. The code is intended for use in a Medicare-approved demonstration project and documents disease status rather than a specific treatment or procedure.
Service type: Oncology disease status assessment / staging-related reporting
Typical site of service: Oncology clinic, hospital outpatient department, or other cancer care setting where staging and disease-status evaluation occur
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a recent colonoscopic biopsy positive for invasive adenocarcinoma of the colon presents to a tertiary academic oncology clinic participating in a Medicare-approved demonstration project. Initial evaluation includes review of pathology confirming adenocarcinoma as the predominant histology and a multidisciplinary staging workflow to determine extent of disease. Imaging studies (contrast-enhanced CT chest/abdomen/pelvis and/or PET-CT), laboratory tests including carcinoembryonic antigen (CEA), and surgical consultation for potential resection or biopsy of suspicious lesions are ordered. The treating medical oncologist documents that disease status is limited to invasive colon adenocarcinoma but that extent of disease is unknown or staging is in progress; the clinic codes the encounter with G9089 to indicate disease status reporting within the demonstration project.
The typical clinical workflow includes:
-
Initial oncology consult and comprehensive history and physical examination.
-
Request and review of prior pathology and colonoscopy reports to confirm adenocarcinoma predominance.
-
Ordering and coordinating staging imaging (CT and/or PET-CT) and targeted diagnostic procedures (image-guided biopsy, diagnostic laparoscopy) as needed.
-
Multidisciplinary tumor board review to finalize stage and plan (surgery, neoadjuvant therapy, or systemic therapy).
-
Documentation that extent of disease is unknown or staging is pending, supporting use of
G9089for the Medicare demonstration project data capture.